OBJECTIVES: Guidelines proposed bioprosthesis implantation for aortic valve disease if the patients were at least 65 years old at the time of surgery, with a trend towards even younger patients in recent years. Considering the adverse effects of lifetime anticoagulation, new biological valves (less prone to degeneration) and new technologies may lead patients and surgeons to different choices. Therefore, it is interesting to analyse the results of aortic bioprosthetic valve replacement in patients aged <65 years at the time of surgery.
INTRODUCTION
Standard aortic valve surgery for both incompetence and degenerative stenosis currently represents the most-performed open heart procedure in developed countries. The decision to implant a biological or a mechanical heart valve prosthesis to replace the diseased native aortic valve depends, among others, on the patient's age at the time of surgery: in particular, standard international guidelines proposed the use of bioprosthesis in elderly patients older than 65-70 years [1, 2] . The last revisions of the ESC/EACTS guidelines from this year expand the indication for bioprostheses and propose that both valve types are acceptable in patients aged between 60 and 65 years at the time of surgery [3] .
An increasing knowledge of the major adverse effects of lifetime anticoagulation, improving technologies in the development of new bioprostheses ( probably less prone to degenerate), the potential option of minimally invasive procedures in case of reoperation and, finally, the individual patient's preference may all lead to a different choice [4] . Interesting successful operative outcomes and satisfactory long-term results after the implantation of standard aortic bioprostheses in patients <65 years of age have recently been reported [5] .
The aim of the present study was to analyse the short-and mid-term results of a selected sample of young patients (<65 years of age) operated on in our institution for aortic valve replacement (AVR) with bioprosthetic heart valves, over a period of 10 years.
The results may be helpful to orientate patients and surgeons, in particular in aortic valve surgery during the early older age period from 55 to 65 years, in their decision-making process.
MATERIALS AND METHODS
We retrospectively reviewed our digital surgery registry to identify patients <65 years of age who underwent primary AVR with a biological heart valve prosthesis in our cardiovascular surgery unit, between January 2000 and December 2010. Patients undergoing redo surgery and congenital heart diseases were excluded from our study. Preoperative and postoperative data were collected and analysed. Moreover, patients were divided into two groups and results were compared: Group A (<56 years of age at the time of surgery) and Group B (between 56 and 64 years of age at the time of surgery). This division was performed according to the postoperative results of a recently published meta-analysis, concluding that no adverse effects on life expectancy could be observed among patients as young as 56 years at the time of surgical aortic bioprosthetic replacement [5] . A mid-term follow-up (FU) was obtained at a mean FU time of 54.4 ± 39.2 months. The outcomes of these patients were compared with those of a control group who underwent isolated mechanical prosthetic AVR at our institution during the same observation and FU period.
Statistical analysis
The statistical analysis was performed using the SPSS 18.0 statistical software package for Windows (SPSS, Inc., Chicago, IL, USA). Continuous variables are summarized as mean ± 1 SD. Categorical variables are presented as counts and proportions (%). Chi-square distribution and t-test were used for univariate statistical calculation and a P-value <0.05 was considered to be statistically significant. The estimated survival and reoperationfree survival curves were computed with the Kaplan-Meier method. The authors had full access to data and take responsibility for their integrity.
Surgical procedures
All patients underwent AVR through a median sternotomy. A standard cannulation was performed in the routine fashion and, since 2005, we have routinely employed the Embol-X™ arterial cannula (Edwards Lifesciences, Irvine, CA, USA) to prevent calcium migration. After having clamped the aorta and arrested the heart with antegrade/retrograde cold blood, or cold crystalloid cardioplegia (St. Thomas) added to topical cooling, the ascending aorta was opened and the valve was replaced, either by a bioprosthesis or by a mechanical prosthesis fixed to the aortic annulus (intra-annular or supra-annular position) using six 2-0 polypropylene running sutures or multiple 2-0 U-fashion single stitches reinforced with pledgets (according to the surgeon's preferences). In the Bentall procedure, the bioprosthesis was, at first, fixated in a woven polyester vascular graft using a 4.0 polypropylene running suture. In concomitant valve or coronary procedures, these were performed following the standard recommendations. Intraoperatively, a 2D transoesophageal echocardiogram was performed routinely.
Concerning anticoagulation, treatment of Warfarin or Coumadin (International normalized ratio (INR) of 2-3) was instituted routinely for 3 months postoperatively and then stopped if not required for other diseases in case of bioprosthetic valve replacement. Systemic anticoagulation (INR range between 2 and 3, according to actual guidelines) was maintained after mechanical AVR. Aspirin was introduced in cases of concomitant coronary disease.
RESULTS

Early follow-up
Bioprosthesis. From January 2000 to December 2010, 84 consecutive patients aged <65 years (mean age 55 ± 12 years, range 22-64 years) underwent standard AVR with biological heart valve prostheses (Fig. 1A) . Regarding the risk factors and previous cardiac events, 52 patients (62%) suffered from hypertension, 18 (21%) from hypercholesterolaemia, 13 had diabetes (15%) and 6 (7%) showed signs of chronic renal insufficiency (serum creatinine level >150 µg/dl). Eighteen patients (21%) had a positive anamnesis of coronary artery disease: in particular, 7 (8%) had previously had an acute myocardial infarction, and of these, 4 (5%) were treated by coronary angioplasty peripheral angioplasty and coronary stent positioning. A medical history for regular tobacco smoking and intravenous drug abuse was found in 21 (25%) and 4 (5%) patients, respectively (Table 1A) .
The aetiology of the valve disease was either degenerative (84.5%) or endocarditic (11%), followed by other rare entities, and the valves were purely stenotic in 50% of patients, regurgitant in 38% or combined (stenosis and regurgitation) in 12% (Table 1B and C). Fifty-five patients (65.5%) had an isolated AVR, 15 (18%) had a combined AVR and coronary bypass surgery, an AVR and ascending aorta replacement was performed in 10 (12%) and a double-valve replacement (aortic and mitral) was performed in 4 (5%) ( Table 1D ). Implanted aortic bioprostheses are listed in Table 1E .
Two patients died in hospital (2.4%): the first died in theatre due to uncontrollable haemorrhage after ascending aortic rupture, whereas the second died postoperatively, at Day 18, in the intensive care unit from severe sepsis and hepatorenal syndrome.
Mechanical prosthesis. A total of 140 patients aged <65 years
(mean 53 ± 9 years, range 23-64 years) underwent isolated mechanical aortic valve prosthetic replacement during the same observation period. Contrary to bioprosthesis implantations, the number of implanted mechanical prostheses decreased progressively ( Fig. 1) . Distribution of risk factors was comparable with the bioprosthetic group, and previous cardiac ischaemic events and concomitant coronary disease were less frequent, due to the selection criteria of patients' data (only isolated mechanical prosthetic valve replacements have been analysed). Thirty-day in-hospital mortality was, with 1.4%, slightly lower compared with the bioprosthesis group, but this difference was not significant. Two patients died in hospital, 10 and 14 days after surgery, of causes not directly cardiac-related (Table 1F) .
Mid-term follow-up
Bioprosthesis. The FU was realized in July 2011, through a phone call by the patient or the attending cardiologist. The mean FU time was 54 ± 39 months (4.5 ± 3 years) and FU completeness was 100%. Eight patients died during the FU, corresponding to an overall late mortality rate of 9.5% (1-and 5-year mortality rate of 0, respectively, 1%). Causes of death were extracardiac in 4% (n = 3), cardiac in 1% (n = 1) and unknown in 5% (n = 4). Mean survival of these patients was 59 ± 37.5 months. The reoperation rate for structural valve degeneration (SVD) during the FU was 6% (5 patients) and occurred 51 ± 25.7 months after the first heart operation ( Table 1F) . The remaining 69 patients were in good cardiac health (all in New York Heart Association functional class I and II) and reported a normal or only marginal decline in their quality of life.
The Kaplan-Meier estimate curves show a cumulative survival rate of 1; 0.97 ± 0.06; 0.92 ± 0.14 and a cumulative reoperation-free survival rate of 0.99 ± 0.02; 0.97 ± 0.06; 0.89 ± 0.18 at 1, 5 and 8 years, respectively (Fig. 2) . Reoperations tended to occur after a longer FU duration (78 months/6.5 years) compared with the mean FU time, and these patients were probably younger at initial surgery (mean age 41 ± 13 years). However, both observations were not significant. Four of the 5 reoperated patients were <50 years of age at the first intervention and the remaining 59-year old patient had to be reoperated after 5 years as a consequence of a proven endocarditis of the bioprosthesis (Table 2) . Transprosthetic mean gradients at echocardiography, of the nonreoperated survivors, were stable during the FU and did not indicate systematic progressive SVD during the FU.
Patients were also divided in two age groups, according to the results of the above-mentioned meta-analysis of Stoica et al.: Group A included patients aged <56 years (29%; n = 24) and Group B patients aged from 56 to 64 years (71%; n = 60), at the time of surgery. The findings revealed a higher risk for reoperation among younger patients (P < 0.02), with a reoperation rate of 17% (n = 4), compared with 2% (n = 1) in Group B. Concerning the late mortality rate, there was no significant difference between the two groups (17%, n = 4; versus 7%, n = 4; P = not significant). Demographic characteristics and risk factors slightly differed between Group A and B as described in Table 1A . A significant difference was also observed concerning valve pathology, with less pure aortic valve stenosis in Group A (17 versus 63%, P < 0.02), and in relation to ventricular function, with less depressed cardiac functions in the younger group (left ventricle ejection fraction of 30-50%: 4 versus 32%, P < 0.05). Endocarditis and post-rheumatic valve disease were more frequent in the younger group (Table 1B) . Regarding the choice of a biological aortic valve in young patients, medical or social contraindications for anticoagulation ( pre-existing neurological events, insufficient compliance, coagulation disorders, young women of child-bearing age, Jehovah's Witness, refusal of blood transfusion and others) were more present in Group A than in Group B (83 versus 32%; P < 0.02), whereas the patient's preference for a bioprosthesis predominated in Group B (Table 1G) .
Mechanical prosthesis. Mean FU time was 56 ± 37 months (4.7 ± 2.8 years). Mechanical prosthesis showed a comparable late mortality rate of 6% (8 patients), with a mean survival of 84 ± 51 months (range 20-144 months). The reoperation rate for prosthetic dysfunction was, with 3% (4 patients) marginally lower, but the difference was not significant, compared with bioprosthesis. Postoperative transprosthetic mean valvular gradients were, with 12 ± 6 mmHg (range 4-25 mmHg, P) similar to the bioprostheses group. Major late neurological complications (either ischaemic or haemorrhagic stroke) occurred predominantly in the mechanical control group, in precisely 10 patients (7%, P < 0.05) at 39 ± 34 months (range 8-110 months) after surgery (Table 1F) .
DISCUSSION
The threshold of patient age for the choice of a biological or a mechanical prosthetic valve in case of standard AVR is today not clearly defined. Guidelines (ESC 2007) proposed until this year a mechanical aortic valve prosthesis for patients <65-70 years of age with a long life expectancy (class IIaC), and a biological heart valve in patients >65-70 years at the time of surgery, with a limited life expectancy and severe comorbidities (class IIaC) [1] . Moreover, the ACC/AHA guidelines from 2006 state that a bioprosthesis is recommended in patients of 65 years of age or above without the risk factors of thromboembolism (class IIaC), but that 'the patient's preference is a reasonable consideration in the selection of aortic . . . valve prosthesis' (class IIaC) [2] . The newest revision of the ESC/EACTS guidelines from 2012 recommends a lower threshold: '. . . in patients aged 60-65 years . . . both valves are acceptable . . .' [3] . Lifetime anticoagulation is the major disadvantage of mechanical heart valves, and there is an increased concrete risk of spontaneous bleeding in older patients treated with full anticoagulation therapy [6] . On the other hand, younger patients with biological heart valves face the risk of SVD [7] . Ongoing development of both bioprostheses with new designs for better haemodynamic performances and new anticalcification treatments to reduce early prosthetic degeneration and, on the other hand, new generation mechanical valves requiring reduced anticoagulation levels make a decision for one type of prosthesis difficult [8, 9] .
ORIGINAL ARTICLE
Moreover, degeneration of bioprostheses has already been treated with a valve-in-valve transcatheter stent-valve procedure, avoiding a higher risk cardiac reoperation [10] [11] [12] .
Even if this is certainly not a standard treatment option today, in the near future it could be an established alternative to open redo surgery. Following these thoughts and new trends in heart valve surgery, the decision-making process with regard to the prosthesis choice should be reviewed: patients with an active lifestyle during their early old age (50-65 years of age) are probably not good candidates for a standard mechanical heart valve requiring long-lasting oral anticoagulation, responsible for a significantly higher incidence of thromboembolic and haemorrhagic central nervous injury in our collective.
Therefore, initial and mid-term results of cohorts of patients <65 years of age, who underwent AVR with biological heart valves, are of major interest.
In the present study, all AVR procedures using bioprostheses were performed successfully, with a 30-day mortality rate of 2.4% and an estimated 5-year survival of 97 ± 6%. During a mean FU time of 4.5 years (with 82 survivors), pure SVD was observed in 4 patients (5%) <50 years of age at the time of surgery, and in 1 older patient who developed endocarditis. The main reason for using a bioprosthesis in patients <56 years at the time of surgery (Group A) was a medical or social contraindication for systemic anticoagulation. Therefore, this group at risk for SVD did not have a real alternative, contrary to patients aged 56-64 years (Group B) who opted for a biological heart valve prosthesis without any evident contraindication to lifetime anticoagulation ( patient's choice in agreement with the surgeon). In the mechanical control group, with a comparable age and gender distribution, we found a tendency towards a lower 30-day mortality rate, which may be explained by the exclusion of more complex surgical procedures and the higher incidence of ischaemic cardiac diseases in the bioprosthesis group. The recently published observation of Badhwar et al. analysing 172 propensitymatched patients, who reported a significantly lower mortality rate at 4-year FU among patients who received a mechanical prosthesis, could not be confirmed in this study [13] . Reoperation rates of both, the bioprosthesis and mechanical prosthesis group, were similar. Bioprosthetic SVD was as frequently in cause as mechanical prosthesis dysfunction. In contrast, a significant higher incidence of central neurological hemorrhagic or thromboembolic complications due to anticoagulation was observed in the mechanical prosthesis group.
Looking at the available literature, analysing bioprosthetic AVR in younger patients, previous studies showed promising results: with a mean FU time of 7.5 years, Al-Khaja et al. described an overall incidence of 26% of reoperations in a cohort of patients receiving bioprosthesis from 1976 to 1982. The different groups aged <40, 40-49, 50-59 and 60-69 years at the time of surgery revealed a reoperation rate of 59, 44, 22 and 7%, respectively, and the authors concluded that surgeons '. . . may be encouraged to use bio-prosthetic heart valves in aortic position in patients over 50 years of age . . .' [14] .
A recently published large retrospective study with a microsimulation of survival and valve-related outcomes in 5433 AVR patients, based on a meta-analysis containing 28 623 patients, concluded that a bioprosthesis can be implanted selectively in patients as young as 56 without significant adverse effects on life expectancy, although event-free life expectancy (mainly SVD) remains significantly lower with a bioprosthesis up to the age of implant of 63 [5] . David et al., after having reviewed 1134 patients operated on for AVR with the Medtronic Hancock II bioprosthesis (mean FU time 12 years), proposed a cut-off at 60 years of age as the '. . . gold standard age . . . ' for bioprosthetic valve implantation. This proposal was also confirmed in another study by Rahimtoola et al. [7, 15] .
Concerning the risk of SVD and redo cardiac surgery, a promising option for a reoperation in elderly patients is the 'valve-in-valve' concept using transcatheter stent-valve prosthesis. This new approach has been described and performed in both stented and stentless aortic bioprostheses and, of course, it cannot be proposed in case of mechanical heart valve dysfunction [10] [11] [12] . In our series, 1 patient >56 years at initial surgery who developed SVD as a consequence of endocarditis was successfully reoperated on 72 months later for symptomatic valve degeneration using a transapical valve-in-valve approach: 6 months later, the patient was in good cardiac condition and asymptomatic. On the other hand, this approach is now certainly not a standard, but a reserve strategy in high-risk redo operations. Furthermore, standard open aortic valve redo surgery for SVD after a bioprosthesis implantation seems to be feasible with a low early 30-day mortality rate [16] .
The present study is limited by the number of patients and by the FU time duration, and it is likely that SVD will increase. Determination of a lower age limit for bioprosthetic aortic valve implantation is difficult, but our data support previous findings, with promising mid-term results, and may help to handle the age limit in a more flexible way. Bioprosthetic AVR could be a treatment alternative for a lower age limit between 56 and 60 years at the time of surgery.
In conclusion, the following observations should be pointed out: (i) the use of an aortic valve bioprosthesis in patients <65 years of age at the time of surgery has increased during the last years, and our experience has confirmed this (Fig. 1); (ii) our results are in line with the available international literature; (iii) patient preference plays a key role in the choice of the valve prosthesis in those who are >56 years of age; (iv) in younger patients (<56 years), the contraindication for anticoagulation guides the choice towards biological valves; (v) in our experience, during the first 4.5-year FU, reoperations for SVD after bioprosthesis implantation occurred exclusively among these, younger patients; (vi) central neurological lesions (either cardiac thromboembolic or haemorrhagic) occurred predominantly in the mechanical prosthesis control group, (vii) alternative transcatheter approaches (valve-in-valve concept) for SVD may probably be a treatment option, avoiding open redo surgery. These observations should be taken into consideration during the decision-making process in patients aged 56-64 years requiring an AVR, in order to avoid systemic anticoagulation.
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